Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25

Author: Benzinga Newsdesk | September 26, 2025 05:55am

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ: ALLR) with a Buy and raises the price target from $9 to $9.25.

Posted In: ALLR